Trial Profile
Phase I Open-Label Dose-Escalating Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of SC-43 Oral Solution in Subjects With Refractory Solid Tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 26 Oct 2020
Price :
$35
*
At a glance
- Drugs SC-43 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors SupremeCure Pharma
- 19 Oct 2020 Planned End Date changed from 1 Nov 2021 to 1 Jun 2023.
- 19 Oct 2020 Planned primary completion date changed from 1 May 2021 to 1 Dec 2022.
- 19 Oct 2020 Planned initiation date changed from 1 Nov 2019 to 1 May 2021.